CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
B Cell LymphomaB Cell Leukemia
Interventions
BIOLOGICAL

Autologous 3rd generation CD19-targeting CAR T cells

Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.

Trial Locations (1)

75185

Uppsala University Hospital, Dept of Oncology, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

AFA Insurance

INDUSTRY

collaborator

Swedish Cancer Society

OTHER

lead

Uppsala University

OTHER

NCT02132624 - CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | Biotech Hunter | Biotech Hunter